🇺🇸 FDA

Intelligence · Clinical Pipeline

Oncology R&D Pipeline

Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Programs
5,568

Quick answer

Oncology: NovaPharmaNews indexes 5,568 oncology clinical pipeline programs from ClinicalTrials.gov with phase, modality, NCT identifiers, and sponsor company links. Anticancer agents, immuno-oncology biologics, and oncology pipeline programs from ClinicalTrials.gov — Phase 1 through approval.

Top sponsors

Page 91 of 116

  1. C-TIL051

    Nektar Therapeutics UK Limited

    Metastatic Non Small Cell Lung Cancer

    phase 1 mab terminated

    1 trial

  2. C5951001- A Phase 1 Study of PF-08046876 in Participants with Advanced Solid Tumors.

    Pfizer Australia Pty Ltd

    advanced solid tumors

    phase 1 other active

    1 trial

  3. C6001001 - A Study to Learn about the Study Medicine PF-08052667 in People with Bladder Cancer.

    Pfizer Australia Pty Ltd

    Non-muscle invasive bladder cancer (NMIBC)

    phase 1 other active

    1 trial

  4. C6081001: A Phase 1 Study of PF-07985045 in Participants with Advanced Solid Tumors

    Pfizer Australia Pty Ltd

    KRAS mutated advanced solid tumors

    phase 1 other active

    1 trial

  5. CAN-2409 + valacyclovir

    Candel Therapeutics

    Lung Cancer

    phase 1 mab completed

    1 trial

  6. CAR T cells

    Qian Wenbin

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  7. CAR T cells chimeric antigenreceptor cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory B-cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  8. CAR T-cell therapy

    Hospital Authority, Hong Kong

    Lymphoblastic Leukemia, Acute, Childhood

    phase 1 mab active

    1 trial

  9. CAR-T Therapy

    Zhao Weili

    Peripheral T Cell Lymphoma

    phase 1 small molecule active

    1 trial

  10. CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Relapsed Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  11. CAR-T cells Infusion chimeric antigen receptor T cells

    The First People's Hospital of Lianyungang

    Relapsed/Refractory Plasma Cell Leukemia

    phase 1 small molecule active

    1 trial

  12. CAR-T cells chimenric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-Cell Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  13. CAR-T cells chimeric antigen receptor T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed/Refractory Acute Myeloid Leukemia(AML)

    phase 1 small molecule active

    1 trial

  14. CAR123 T cell treatment of relapsed/refractory hematologic malignancies.

    The George Institute

    Relapsed/refractory CD123+ hematological malignancies: Acute Myeloid Leukemia, Myelodysplastic Syndrome, Blastic Plasmacytoid Dendritic Cell Neoplasm, Acute Lymphoblastic Leukemia.

    phase 1 other active

    1 trial

  15. CART19 cell and auto-HSCT

    Shenzhen Second People's Hospital

    Leukemia, Lymphocytic, Acute, B-Cell

    phase 1 mab active

    1 trial

  16. CART19 cells effects in patients with relapsed/refractory acute lymphoblastic leukemia and non-Hodgkin lymphoma.

    The George Institute

    Relapsed/refractory CD19+ Acute Lymphoblastic Leukaemia and Non-Hodgkin Lymphoma

    phase 1 other active

    1 trial

  17. CARTmeso CART19

    The First People's Hospital of Lianyungang

    Pancreatic Cancer

    phase 1 mab active

    1 trial

  18. CB-010

    Caribou Biosciences

    Lymphoma, Non-Hodgkin

    phase 1 gene therapy active

    1 trial

  19. CB-012

    Caribou Biosciences

    Acute Myeloid Leukemia, in Relapse

    phase 1 small molecule terminated

    1 trial

  20. CBG131 CAR-T Cell Infusion

    The First People's Hospital of Lianyungang

    Advanced Gastric and Pancreatic Cancer

    phase 1 small molecule active

    1 trial

  21. CC-122

    Bristol-Myers Squibb

    Non-Hodgkin Lymphoma

    phase 1 small molecule active

    1 trial

  22. CC-486

    Celgene Europe Limited

    Leukemia, Myeloid, Acute

    phase 1 small molecule completed

    1 trial

  23. CCT3833

    United Therapeutics Europe Ltd

    Melanoma

    phase 1 small molecule completed

    1 trial

  24. CD-001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Malignant Neoplasm

    phase 1 small molecule active

    1 trial

  25. CD105/Yb-1/SOX2/CDH3/MDM2-polyepitope Plasmid DNA Vaccine

    United Therapeutics Europe Ltd

    HER2 Negative Breast Carcinoma

    phase 1 mab active

    1 trial

  26. CD123+CLL-1 dual-target CAR-T cells sequential infusion CD7 CAR-T cells and bridging to allogeneic

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    AML - Acute Myeloid Leukemia

    phase 1 mab active

    1 trial

  27. CD19-CD22 CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Relapsed or Refractory B Cell Acute Lymphoblastic Leukemia

    phase 1 mab terminated

    1 trial

  28. CD19-TriCAR-T/SILK

    Biotech Pharmaceutical Co.,

    Non-Hodgkin Lymphoma

    phase 1 mab active

    1 trial

  29. CD19/CD20 Dual-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Leukemia

    phase 1 mab completed

    1 trial

  30. CD19/CD20 Dual-CAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    B-cell Non-Hodgkin's Lymphoma

    phase 1 mab on hold

    1 trial

  31. CD7 UCAR-T cells

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    T-cell Leukemia

    phase 1 mab active

    1 trial

  32. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Ovarian Cancer

    phase 1 mab active

    1 trial

  33. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma

    phase 1 mab active

    1 trial

  34. CD70 CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Metastatic Tumor

    phase 1 mab active

    4 trials

  35. CD70-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Renal Cell Carcinoma (RCC)

    phase 1 mab active

    1 trial

  36. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  37. CEA CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Gastric Cancer

    phase 1 mab active

    1 trial

  38. CEA protein antigen plus BCG Vaccine Mix for percutaneous use

    Lxo Ireland Designated Activity Company

    Rectal Cancer

    phase 1 mab active

    1 trial

  39. CEA-targeted CAR-T (Intravenous)

    Chongqing Precision Biotech Co., Ltd

    NSCLC (Advanced Non-small Cell Lung Cancer)

    phase 1 mab active

    1 trial

  40. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Peritoneal Metastases From Colorectal Cancer

    phase 1 mab active

    1 trial

  41. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Colorectal Cancer

    phase 1 mab active

    1 trial

  42. CEA-targeted CAR-T cells

    Chongqing Precision Biotech Co., Ltd

    Lung Cancer

    phase 1 mab active

    1 trial

  43. CEND-1

    LISATA THERAPEUTICS, INC.

    Pancreatic Cancer

    phase 1 small molecule completed

    1 trial

  44. CEP-11981 (kinase inhibitor)

    Teva Pharma GmbH

    Cancer

    phase 1 small molecule completed

    1 trial

  45. CEP-37440

    Teva Pharma GmbH

    Solid Tumors

    phase 1 small molecule completed

    1 trial

  46. CEP-9722

    Teva Pharma GmbH

    Solid Tumor

    phase 1 small molecule completed

    1 trial

  47. CEP-9722

    Teva Pharma GmbH

    Solid Tumors or Mantle Cell Lymphoma

    phase 1 small molecule completed

    1 trial

  48. CFT1946

    C4 Therapeutics

    Solid Tumors

    phase 1 small molecule completed

    1 trial

Frequently asked questions

How many oncology pipeline programs are tracked?

5,568 programs match this therapeutic area based on indication text, program name, and registry metadata.

Where does pipeline data come from?

ClinicalTrials.gov records linked to NovaPharmaNews company profiles. Verify on ClinicalTrials.gov before investment decisions.

Data attribution: Data sources · All pipeline programs

Drug approvals, clinical trials, M&A, event intelligence, and company updates — weekly.

Customize topics & region
Topics
Region

No spam. Unsubscribe anytime. See our privacy policy.